Alnylam Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Yvonne L. Greenstreet
- Full Time Employees
- 2,500
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 675 West Kendall Street Cambridge MA United States of America 02142
- IPO Date
- Jun 1, 2004
- CIK
- 0001178670
- Website
- alnylam.com
- Similar Companies
- Business
- Alnylam Pharmaceuticals, Inc. (ALNY) develops and commercializes RNA interference (RNAi) therapeutics targeting genetically defined diseases; core products include ONPATTRO (patisiran) for hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy, AMVUTTRA (vutrisiran) for ATTR amyloidosis with polyneuropathy or cardiomyopathy, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1; the company also advances partnered programs such as Leqvio (inclisiran) for hypercholesterolemia marketed by Novartis. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam operates globally with key facilities in the US, Europe (including France, Italy, Netherlands, Sweden, Switzerland, and the UK), and Japan. The company maintains strategic collaborations with Roche on zilebesiran for hypertension, Regeneron for CNS diseases, Sanofi on fitusiran for hemophilia, and others including Novartis and Agios Pharmaceuticals. Recent developments encompass expansion of AMVUTTRA into ATTR cardiomyopathy with strong launch uptake and upgraded 2025 revenue guidance, initiation of a Phase 1 trial for ALN-4324 targeting GRB14 for type 2 diabetes, and Agios' IND clearance for AG-236 (ALN-TMP) in polycythemia vera; Alnylam joined the Alliance for Genomic Discovery in 2025 to leverage datasets for gene-silencing medicines and extended its partnership with Medison Pharma into LATAM and APAC markets. Pipeline advancements feature nucresiran for ATTR amyloidosis, mivelsiran for Alzheimer's disease and cerebral amyloid angiopathy, and positive Phase 3 data for zilebesiran. These efforts support Alnylam's transition to profitability with 2024 net product revenues exceeding $1.3 billion across rare and cardiometabolic indications.
Company News
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $386.14 Consensus Target Price from Analysts
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
ALNY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alnylam Pharmaceuticals, Inc.
Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026
(NASDAQ: ALNY) Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. Investors to Contact the Firm
(NASDAQ: ALNY) Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. Investors to Contact the Firm
NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm
Biotech Is Booming, But These 2 Stocks Missed the Memo
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
ALNY SHAREHOLDER ALERT: Alnylam Pharmaceuticals, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
ALNY SHAREHOLDER ALERT: Alnylam Pharmaceuticals, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm
Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm